Hostname: page-component-76fb5796d-dfsvx Total loading time: 0 Render date: 2024-04-25T10:09:54.520Z Has data issue: false hasContentIssue false
  • English
  • Français

Three case reports of emergent dyskinesia with clozapine

Published online by Cambridge University Press:  16 April 2020

Rafael Gafoor  and
Justin Brophy
Rafael Gafoor*
Affiliation:
Division of Psychological Medicine, Institute of Psychiatry, Kings College of London, de Crespigny Park, Denmark Hill, LondonSE5 8AF, UK
Justin Brophy
Affiliation:
Newcastle Hospital, Greystones, Co. Wicklow, Republic of Ireland
*
2Corresponding author. r.gafoor@iop.kcl.ac.uk
Get access

Abstract

Clozapine is indicated for the treatment of patients intolerant of conventional antipsychotic agents. It is often used to treat those patients who have developed movement disorders while on conventional antipsychotics. We report three cases of dyskinesia associated with clozapine induction. We suggest a mechanism that might explain an underlying dopaminergic hypersensitivity during this transitional period. Further, we identify groups that might be at high risk of developing dyskinesia and suggest strategies to reduce risk especially in these groups.

Keywords

ClozapineEmergent dyskinesiaMovement disordersTardive dyskinesiaSchizophreniaWithdrawal dyskinesia
Type
Case report
Information
European Psychiatry , Volume 18 , Issue 5 , August 2003 , pp. 260 - 261
Copyright
Copyright © Éditions scientifiques et médicales Elsevier SAS 2003

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Baldessarini, RJ. A summary of current knowledge of tardive dyskinesia. Encephale 1988;14 Spec No:263–8.Google ScholarPubMed
Borison, RL. Changing antipsychotic medication: guidelines on the transition to treatment with risperidone. The Consensus Study Group on Risperidone Dosing. Clin Ther 1996;18(4):592–607.10.1016/S0149-2918(96)80211-6CrossRefGoogle Scholar
Glazer, WM. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry 2000;61(Suppl 3):16–21.Google ScholarPubMed
Jann, MW. Clozapine. Pharmacotherapy 1991;11(3):179–95.Google ScholarPubMed
Kane, J, Woerner, M, Pollack, S, Safferman, AZ, Lieberman, J.Does Clozapine Cause Tardive Dyskinesia? J Clin Psychiatry 1993;54: 327–30.Google ScholarPubMed
Masand, PS. Side effects of antipsychotics in the elderly. J Clin Psychiatry 2000;61(Suppl 8):43–9.Google ScholarPubMed
Schneider, JS, Wade, T, Lidsky, TI.Chronic neuroleptic treatment alters expression of glial glutamate transporter GLT-1 mRNA in the striatum. Neuroreport 1998;9(1):133–6.CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.